These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7984654)

  • 1. Enhancement of striatal lipid peroxidation induced by 1-methyl-4-phenylpyridinium in mouse brain is blocked by MAO-B inhibitors.
    Ríos C; Bravo-Velazquez S; Altagracia M; Kravzov J
    Proc West Pharmacol Soc; 1994; 37():159-60. PubMed ID: 7984654
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
    Barbelivien A; Nyman L; Haapalinna A; Sirviö J
    Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors: electrospray-MS analysis of intra-striatal microdialysates.
    Boismenu D; Mamer O; Ste-Marie L; Vachon L; Montgomery J
    J Mass Spectrom; 1996 Oct; 31(10):1101-8. PubMed ID: 8916419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
    Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
    J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
    Murphy DL; Lipper S; Slater S; Shiling D
    Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of lipid peroxidation by monoamine oxidase enzyme inhibitors.
    Szökö E; Báthory G; Magyar K
    Acta Physiol Hung; 1990; 75 Suppl():269-70. PubMed ID: 2115231
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
    Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A.
    Alves E; Summavielle T; Alves CJ; Custódio JB; Fernandes E; de Lourdes Bastos M; Tavares MA; Carvalho F
    Addict Biol; 2009 Apr; 14(2):185-93. PubMed ID: 19076925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl.
    Andoh T; Chock PB; Murphy DL; Chiueh CC
    Mol Pharmacol; 2005 Nov; 68(5):1408-14. PubMed ID: 16099847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors.
    Moskvitina TA; Medvedev AE
    Med Sci Monit; 2001; 7(1):17-9. PubMed ID: 11208486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinetics of inhibition of type-B monoamine oxidase by clorgyline, pargyline and (-)-deprenyl.
    Green AL
    J Pharm Pharmacol; 1981 Dec; 33(12):798-800. PubMed ID: 6121857
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum.
    Kitanaka N; Kitanaka J; Takemura M
    Neuroscience; 2005; 130(2):295-308. PubMed ID: 15664686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative effects of irreversible MAO inhibitors in vivo.
    Felner AE; Waldmeier PC
    Biochem Pharmacol; 1979 Apr; 28(7):995-1002. PubMed ID: 444293
    [No Abstract]   [Full Text] [Related]  

  • 15. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP; Lamensdorf I; Armoni T
    Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay.
    Guang HM; Du GH
    Acta Pharmacol Sin; 2006 Jun; 27(6):760-6. PubMed ID: 16723097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
    Aguiar LM; Macêdo DS; Vasconcelos SM; Oliveira AA; de Sousa FC; Viana GS
    Brain Res; 2008 Jan; 1191():192-9. PubMed ID: 18164694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition.
    Le W; Jankovic J; Xie W; Kong R; Appel SH
    Neurosci Lett; 1997 Mar; 224(3):197-200. PubMed ID: 9131670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible melatonin involvement in the hypotensive effect of MAO inhibitors.
    Oxenkrug GF; McCauley RB; Fontana DJ; McIntyre IM; Commissaris RL
    J Neural Transm; 1986; 66(3-4):271-80. PubMed ID: 3097249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.